Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 24 September 2019, 09:01 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress

TOKYO, Sept 24, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019. The abstracts highlight updates regarding Eisai's in-house discovered LENVIMA (lenvatinib mesylate, the orally available kinase inhibitor, "lenvatinib"), and Halaven (eribulin mesylate, "eribulin", halichondrin class microtubule dynamics inhibitor).

At the ESMO 2019 Congress, there will be an oral presentation of results from the final analysis of the endometrial carcinoma cohort of Study 111/KEYNOTE-146, a Phase Ib/II study evaluating the combination treatment of lenvatinib and Merck & Co., Inc., Kenilworth, NJ., U.S.A.'s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in select solid tumors (Abstract No.: 994O). The combination treatment was the first to be approved in the United States, Australia and Canada under the U.S. Food and Drug Administration's Project Orbis in Sept 2019

A total of 11 poster presentations are scheduled, including one on the updated results of the lenvatinib plus pembrolizumab combination treatment in unresectable hepatocellular carcinoma in study 116/KEYNOTE- 524, a Phase 1b study (Abstract No.: 747P), and the interim analysis evaluating the combination after disease progression after PD-1/PD-L1 immune checkpoint blockade in renal cell carcinoma (RCC) from 111/KEYNOTE-146 RCC cohort (Abstract No.: 1187PD). In addition, the latest data from a Phase I study for an eribulin liposomal formulation in solid tumors (Abstract No.: 348P) will be presented.

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.


About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:
Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Sept 24, 2019 09:01 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
June 4, 2020 10:43 HKT/SGT
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
June 2, 2020 10:05 HKT/SGT
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
May 29, 2020 14:54 HKT/SGT
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 10:31 HKT/SGT
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 18, 2020 12:33 HKT/SGT
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 14, 2020 08:22 HKT/SGT
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
Apr 27, 2020 16:26 HKT/SGT
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
Apr 1, 2020 15:23 HKT/SGT
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
Mar 26, 2020 16:01 HKT/SGT
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)
Mar 25, 2020 08:38 HKT/SGT
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: